RUA Gold
Follow

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Disclaimer
Radius Research Radius Research

Radius Research

meticulous due diligence. Under the astute leadership of Founder Martin Gagle, the firm has embarked on a mission to demystify the investment landscape, one insightful conversation at a time. Martin hosts a weekly video series, engaging in enlightening discussions with C-suite executives from every corner of the globe, thereby bridging the informational chasm that often exists between companies and potential investors. This initiative not only shines a light on the visions and ventures of seasoned CEOs but also unveils emerging companies poised to make a significant impact in the industry. Radius Research transcends the conventional advisory role by facilitating a platform where ideas exchange hands and trust is the currency. The firm’s offerings are not just robust but come with a stamp of Institutional Quality, ensuring clients are well-equipped with the acumen necessary to navigate the complex financial waters. Through its unwavering commitment to transparency and quality, Radius Research Investments is not just a service provider, but a companion in the investment journey.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0)
This video was produced on behalf of the presenting company.

CEO Corey Giasson
COO Colin Bletsky
@MustGrowBio
$MGRO $MGROF $0C0
#MGRO #agriculture #biotech #AG #agritech #sustainability #cropprotection
https://mustgrow.ca/
MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers.  In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products.  These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers.  Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies.  The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg.  MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 52.4 million common shares issued and outstanding and 59.4 million shares fully diluted. For further details, please visit www.mustgrow.ca.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0)
This video was produced on behalf of the presenting company.

CEO Corey Giasson
COO Colin Bletsky
@MustGrowBio
$MGRO $MGROF $0C0
#MGRO #agriculture #biotech #AG #agritech #sustainability #cropprotection
https://mustgrow.ca/
MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 52.4 million common shares issued and outstanding and 59.4 million shares fully diluted. For further details, please visit www.mustgrow.ca.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLkVZcUU0cm9aaFFz

MustGrow Biologics (MGRO) Q1 Financial Results $3.8 million revenue, CEO Corey Giasson

Radius Research 90 minutes ago

Primary Hydrogen (HDRO) Natural Hydrogen Exploration and Development CEO Ben Asuncion

Radius Research 90 minutes ago

Sabio Holdings Inc. (TSXV: SBIO) (OTCQB: SABOF)
This video was produced on behalf of the presenting company.

CEO Aziz Rahimtoola and CFO Sajid Premji present Q1 financial results and take questions from the audience.

https://www.sabioholding.com/
Sabio Holdings is a technology and services leader in the fast-growing ad-supported streaming space. Its cloud-based, end-to-end technology stack helps top global brands and agencies reach, engage and validate streaming audiences. Sabio consists of: a proprietary ad-serving technology platform that partners with the top ad-supported streaming platforms and apps in the world; App Science, a non-cookie-based software-as-a-service analytics and insights platform with artificial intelligence natural language capabilities; and Creator Television, the first creator-led streaming network and content studio dedicated to bringing the authenticity and energy of social-media storytelling to TV.

THIS VIDEO IS PRODUCED ON BEHALF OF THE PRESENTING COMPANY

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

Sabio Holdings Inc. (TSXV: SBIO) (OTCQB: SABOF)
This video was produced on behalf of the presenting company.

CEO Aziz Rahimtoola and CFO Sajid Premji present Q1 financial results and take questions from the audience.

https://www.sabioholding.com/
Sabio Holdings is a technology and services leader in the fast-growing ad-supported streaming space. Its cloud-based, end-to-end technology stack helps top global brands and agencies reach, engage and validate streaming audiences. Sabio consists of: a proprietary ad-serving technology platform that partners with the top ad-supported streaming platforms and apps in the world; App Science, a non-cookie-based software-as-a-service analytics and insights platform with artificial intelligence natural language capabilities; and Creator Television, the first creator-led streaming network and content studio dedicated to bringing the authenticity and energy of social-media storytelling to TV.

THIS VIDEO IS PRODUCED ON BEHALF OF THE PRESENTING COMPANY

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLlR3UlNHRFh4NHVR

Sabio Holdings (SBIO) Q1 Results: 43% Revenue Growth 91% reocurring Revenue Rate CEO Aziz Rahimtoola

Radius Research 90 minutes ago

THIS VIDEO IS PRODUCED ON BEHALF OF THE PRESENTING COMPANY
CEO Joseph Walewicz will discuss the company's recent financial results, growth plans and opportunities.

Growing Healthcare Clinics

@NeuPathHealth
$NPTH
#NPTH #neupathhealth #chronicpainmanagement #acupuncturerelief #chronicpainsolutions #healthcare #wellness
https://www.neupath.com/
NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

THIS VIDEO IS PRODUCED ON BEHALF OF THE PRESENTING COMPANY
CEO Joseph Walewicz will discuss the company's recent financial results, growth plans and opportunities.

Growing Healthcare Clinics

@NeuPathHealth
$NPTH
#NPTH #neupathhealth #chronicpainmanagement #acupuncturerelief #chronicpainsolutions #healthcare #wellness
https://www.neupath.com/
NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLlY2a2dPWmgzZUNN

NeuPath Health (NPTH) CEO Joe Walewicz Reviews Strong Q1 Results - Cash Generation & Growth

Radius Research May 25, 2025 4:05 pm

THIS VIDEO IS PRODUCED ON BEHALF OF THE PRESENTING COMPANY
May 21, 2025 /CNW/ - Odd Burger Corporation ("Odd Burger" or the "Company") (TSXV: ODD) (OTCPK: ODDAF) (FSE: IA9) is pleased to announce that it has received approval to list its retail product line at 7-Eleven Canada ("7-Eleven") in over 500 locations across Canada.

@oddburger
$ODD $GBLYF
#oddburger #plantbased #plantbasedmeals #plantpowered #shopvegan #veganfood
https://oddburger.com/
Odd Burger Corporation is a franchised vegan fast-food restaurant chain and food technology company that manufactures a proprietary line of plant-based protein and dairy alternatives. Its manufactured products are distributed to Odd Burger restaurant locations through its foodservice line and also sold at grocery retailers through its consumer-packaged goods (CPG) line. Odd Burger restaurants operate as smart kitchens, which use state-of-the art cooking technology and automation solutions to deliver a delicious food experience to customers craving healthier and more sustainable fast food. With small store footprints optimized for delivery and takeout, advanced cooking technology, competitive pricing, a vertically integrated supply chain along with healthier ingredients, Odd Burger is revolutionizing the fast-food industry by creating guilt-free fast food that can be enjoyed at its restaurant locations or at home though its CPG line. Odd Burger Corporation is traded on the TSX Venture Exchange under the symbol "ODD" and on the OTCPK under the symbol "ODDAF". For more information visit https://www.oddburger.com.

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

THIS VIDEO IS PRODUCED ON BEHALF OF THE PRESENTING COMPANY
May 21, 2025 /CNW/ - Odd Burger Corporation ("Odd Burger" or the "Company") (TSXV: ODD) (OTCPK: ODDAF) (FSE: IA9) is pleased to announce that it has received approval to list its retail product line at 7-Eleven Canada ("7-Eleven") in over 500 locations across Canada.

@oddburger
$ODD $GBLYF
#oddburger #plantbased #plantbasedmeals #plantpowered #shopvegan #veganfood
https://oddburger.com/
Odd Burger Corporation is a franchised vegan fast-food restaurant chain and food technology company that manufactures a proprietary line of plant-based protein and dairy alternatives. Its manufactured products are distributed to Odd Burger restaurant locations through its foodservice line and also sold at grocery retailers through its consumer-packaged goods (CPG) line. Odd Burger restaurants operate as smart kitchens, which use state-of-the art cooking technology and automation solutions to deliver a delicious food experience to customers craving healthier and more sustainable fast food. With small store footprints optimized for delivery and takeout, advanced cooking technology, competitive pricing, a vertically integrated supply chain along with healthier ingredients, Odd Burger is revolutionizing the fast-food industry by creating guilt-free fast food that can be enjoyed at its restaurant locations or at home though its CPG line. Odd Burger Corporation is traded on the TSX Venture Exchange under the symbol "ODD" and on the OTCPK under the symbol "ODDAF". For more information visit https://www.oddburger.com.

Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLjZERWNURVR2WlVV

Odd Burger (ODD) CEO James McInnes - Launching Products in over 500 7-Eleven Stores Canada

Radius Research May 22, 2025 2:26 pm

BirchTech (BCHT) CEO Richard MacPherson - Q1 Review and 2025/26 Outlook and Milestones

Radius Research May 22, 2025 2:26 pm

THIS VIDEO IS PRODUCED ON BEHALF OF THE PRESENTING COMPANY

@Burcon
$BU $BRCN
#BU #Burcon #plantbasedfoods #canolaprotein #peaprotein #soyprotein #hempprotein #sustainable
https://burcon.ca/
Burcon is a global technology leader in the development of plant-based proteins for foods and beverages.  Our proteins exhibit superior functionality, taste and nutrition, making them ideal ingredients for food formulators.  With over two decades of experience, Burcon has amassed an extensive patent portfolio covering its novel plant-based proteins derived from pea, canola, soy, hemp and sunflower seeds, among other plant sources.  Burcon is striving to become a vertically integrated provider of specialty plant-based protein solutions that deliver on health, nutrition and sustainability.  Supporting the growing trend towards a plant-based diet, Burcon is developing premium protein ingredients that we believe are better for you and better for the planet.



Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

THIS VIDEO IS PRODUCED ON BEHALF OF THE PRESENTING COMPANY

@Burcon
$BU $BRCN
#BU #Burcon #plantbasedfoods #canolaprotein #peaprotein #soyprotein #hempprotein #sustainable
https://burcon.ca/
Burcon is a global technology leader in the development of plant-based proteins for foods and beverages. Our proteins exhibit superior functionality, taste and nutrition, making them ideal ingredients for food formulators. With over two decades of experience, Burcon has amassed an extensive patent portfolio covering its novel plant-based proteins derived from pea, canola, soy, hemp and sunflower seeds, among other plant sources. Burcon is striving to become a vertically integrated provider of specialty plant-based protein solutions that deliver on health, nutrition and sustainability. Supporting the growing trend towards a plant-based diet, Burcon is developing premium protein ingredients that we believe are better for you and better for the planet.



Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLl9BMUJSWEp1UFhZ

Burcon NutraScience (BU) Burcon's Broad Portfolio of Proteins CEO Kip Underwood

Radius Research May 20, 2025 2:35 pm

THIS VIDEO WAS PRODUCED ON BEHALF OF THE PRESENTING COMPANY

CEO James Helliwell is reviewing the recently published Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI.

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

2025-05-05 16:37 ET - News Release


Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI
At 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoE
Also, at 9 months patients demonstrated sustained or improved treatment outcomes compared to 3- and 6-month results
Additional long-term data to be released with higher doses in Q3 2025
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

2025-05-05 16:37 ET - News Release


Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI
At 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoE
Also, at 9 months patients demonstrated sustained or improved treatment outcomes compared to 3- and 6-month results
Additional long-term data to be released with higher doses in Q3 2025

THIS VIDEO IS PRODUCED ON BEHALF OF THE PRESENTING COMPANY
Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

THIS VIDEO WAS PRODUCED ON BEHALF OF THE PRESENTING COMPANY

CEO James Helliwell is reviewing the recently published Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI.

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

2025-05-05 16:37 ET - News Release


Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI
At 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoE
Also, at 9 months patients demonstrated sustained or improved treatment outcomes compared to 3- and 6-month results
Additional long-term data to be released with higher doses in Q3 2025
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

2025-05-05 16:37 ET - News Release


Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI
At 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoE
Also, at 9 months patients demonstrated sustained or improved treatment outcomes compared to 3- and 6-month results
Additional long-term data to be released with higher doses in Q3 2025

THIS VIDEO IS PRODUCED ON BEHALF OF THE PRESENTING COMPANY
Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.

YouTube Video VVU4ZG9IXzVRY19YbmlxZlRRMmM5Y0FnLjVadVlCNFVRRS1v

Eupraxia Pharmaceuticals (EPRX) CEO James Helliwell: Positive 1b/2a Resolve 9-Month Trial Data

Radius Research May 18, 2025 4:14 pm

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Disclaimer